A Phase 2 interventional study of LCP-Tacro tablets and Prograf in Renal Failure, sponsored by Veloxis Pharmaceuticals. Completed at 13 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-07-07.
Sponsored by Veloxis Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing tacrolimus in Renal Insufficiency — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Renal Insufficiency.
Among the 17 studies testing tacrolimus in Renal Insufficiency, this one is the 14th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 12th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →None of the 17 studies testing tacrolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 6 · Phase 4 6
First in 2003; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 50 across the 17 interventional studies. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 17 have an industry lead sponsor. The 9 most frequent:
Veloxis Pharmaceuticals is the lead sponsor of 18 studies on the registry; 1 is open to participants now.
Veloxis Pharmaceuticals has 9 studies filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing tacrolimus in Renal Insufficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
This is a 2-arm , parallel group, prospective, double-blind, double-dummy, multicenter,clinical trial to evaluate the pharmacokinetics of LCP-Tacro tablets once daily in comparison to Prograf capsules twice-daily after kidney transplantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Donor with positive serological test result for HIV-1, HBV or HCV Donor with history of malignant disease (current or historical) Cold ischemia time >30 hours Non-heart-beating donor
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
Drug: LCP-Tacro tablets
Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
Drug: Prograf
Tacrolimus
Also known as: Prograf
Tacrolimus
Also known as: Prograf Capsules twice daily
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (AUC) was evaluated on Day 1 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.
Time frame: 1 days
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (AUC) was evaluated on Day 14 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.
Time frame: 14 days
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (AUC) was evaluated on Day 28 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.
Time frame: 28 days
Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 1 in adult de novo kidney recipients.
Time frame: 1 days
Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 14 in adult de novo kidney recipients.
Time frame: 14 days
Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 28 in adult de novo kidney recipients.
Time frame: 28 days
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Tmax) was evaluated on Day 1 in adult de novo kidney recipients.
Time frame: 1 days
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Tmax) was evaluated on Day 14 in adult de novo kidney recipients.
Time frame: 14 days
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Tmax) was evaluated on Day 28 in adult de novo kidney recipients.
Time frame: 28 days
Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Fluctuation) was evaluated on Day 14 in adult de novo kidney recipients.
Time frame: 14 days
Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation
The pharmacokinetic parameter (Fluctuation) was evaluated on Day 28 in adult de novo kidney recipients.
Time frame: 28 days
Daytime, Nighttime and Overnight Systolic Blood Pressure (SBP) on Day 14.
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.
Time frame: 14 days
Daytime, Nighttime Overnight Systolic Blood Pressure (SBP) on Day 28.
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Day 28.
Time frame: 28 days
Ratio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 14.
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.
Time frame: 14 days
Ratio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 28.
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 28.
Time frame: 28 days
Evaluation of the Short-term Efficacy of LCP-Tacro After the Start of Dosing.
The efficacy is measured by the number of treatment failures defined as all-cause mortality, Graft Failure, Biopsy Proven Acute Rejection (BPAR) and Lost to follow up.
Time frame: 30 days
| Milestone | LCP-Tacro | Prograf |
|---|---|---|
| Started | 18 | 18 |
| Completed | 17 | 17 |
| Not completed | 1 | 1 |
| Withdrew: Not dosed | 1 | 1 |
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.
| mmHg | LCP-Tacro | Prograf |
|---|---|---|
| Daytime SBP | 140.96 ± 10,311 | 131.54 ± 13.835 |
| Nighttime SBP | 140.69 ± 9.147 | 133.38 ± 17.875 |
| Overnight SBP | 140.80 ± 10.347 | 132.54 ± 18.127 |
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Day 28.
| mmHg | LCP-Tacro | Prograf |
|---|---|---|
| Daytime SBP | 139.05 ± 14.722 | 130.84 ± 15.754 |
| Nighttime SBP | 137.18 ± 13.283 | 129.09 ± 16.447 |
| Overnight SBP | 136.11 ± 13.539 | 127.70 ± 16.599 |
The pharmacokinetic parameter (AUC) was evaluated on Day 1 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.
| ng*hr/mL | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 382.72 ± 233.84 | 147.82 ± 85.31 |
The pharmacokinetic parameter (AUC) was evaluated on Day 14 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.
| ng*hr/mL | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 371.43 ± 133.85 | 244.63 ± 66.92 |
The pharmacokinetic parameter (AUC) was evaluated on Day 28 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.
| ng*hr/mL | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 357.39 ± 146.64 | 205.79 ± 36.25 |
The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 1 in adult de novo kidney recipients.
| ng/mL | LCP-Tacro | Prograf |
|---|---|---|
| Cmax | 32.68 ± 20.51 | 12.97 ± 7.08 |
| C24 | 13.32 ± 8.89 | 5.72 ± 5.28 |
The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 14 in adult de novo kidney recipients.
| ng/mL | LCP-Tacro | Prograf |
|---|---|---|
| Cmax | 30.08 ± 14.27 | 18.98 ± 6.59 |
| C24 | 9.11 ± 2.86 | 7.54 ± 2.50 |
The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 28 in adult de novo kidney recipients.
| ng/mL | LCP-Tacro | Prograf |
|---|---|---|
| Cmax | 32.51 ± 18.74 | 17.38 ± 4.07 |
| C24 | 9.31 ± 3.44 | 6.75 ± 2.22 |
The pharmacokinetic parameter (Tmax) was evaluated on Day 1 in adult de novo kidney recipients.
| hour | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 11.26 ± 7.49 | 7.39 ± 6.37 |
The pharmacokinetic parameter (Tmax) was evaluated on Day 14 in adult de novo kidney recipients.
| hour | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 7.03 ± 5.69 | 5.03 ± 5.81 |
The pharmacokinetic parameter (Tmax) was evaluated on Day 28 in adult de novo kidney recipients.
| hour | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 5.69 ± 4.11 | 7.69 ± 6.87 |
The pharmacokinetic parameter (Fluctuation) was evaluated on Day 14 in adult de novo kidney recipients.
| Percentage of fluctuation | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 126.86 ± 57.65 | 114.73 ± 52.36 |
The pharmacokinetic parameter (Fluctuation) was evaluated on Day 28 in adult de novo kidney recipients.
| Percentage of fluctuation | LCP-Tacro | Prograf |
|---|---|---|
| Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation | 144.78 ± 84.63 | 131.4 ± 75.96 |
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.
| ratio | LCP-Tacro | Prograf |
|---|---|---|
| Night:Day ratio SBP | 0.99 ± 0.035 | 1.01 ± 0.057 |
| Overnight:Day Ratio SBP | 1.00 ± 0.053 | 1.01 ± 0.057 |
At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 28.
| ratio | LCP-Tacro | Prograf |
|---|---|---|
| Night:Day ratio SBP | 0.99 ± 0.035 | 0.98 ± 0.067 |
| Overnight:Day Ratio SBP | 0.99 ± 0.064 | 0.98 ± 0.067 |
The efficacy is measured by the number of treatment failures defined as all-cause mortality, Graft Failure, Biopsy Proven Acute Rejection (BPAR) and Lost to follow up.
| participants | LCP-Tacro | Prograf |
|---|---|---|
| All-cause mortality | 0 | 0 |
| Graft Failure | 0 | 0 |
| BPAR | 2 | 0 |
| Lost to follow up | 0 | 0 |
Collected over Adverse events were collected from start of study drug and until 30 days after last dose of study drug for at total of 2 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LCP-Tacro | — | 5/17 (29.4%) | 17/17 (100%) |
| Prograf | — | 5/17 (29.4%) | 17/17 (100%) |
| Event | LCP-Tacro | Prograf |
|---|---|---|
| Kidney transplant rejectionImmune system disorders | 2/17 | 0/17 |
| Angina PectorisCardiac disorders | 1/17 | 0/17 |
| Atrial FibrilationCardiac disorders | 1/17 | 0/17 |
| Ventricular TachycardiaCardiac disorders | 0/17 | 1/17 |
| NauseaGastrointestinal disorders | 1/17 | 1/17 |
| VomitingGastrointestinal disorders | 1/17 | 1/17 |
| Pelvic AbscessInfections and infestations | 1/17 | 0/17 |
| SepsisInfections and infestations | 0/17 | 1/17 |
| Wound infectionInfections and infestations | 0/17 | 1/17 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/17 | 1/17 |
| Event | LCP-Tacro | Prograf |
|---|---|---|
| ConstipationGastrointestinal disorders | 6/17 | 7/17 |
| DiarrhoeaGastrointestinal disorders | 4/17 | 2/17 |
| Oedema peripheralGeneral disorders | 4/17 | 0/17 |
| TremorNervous system disorders | 4/17 | 2/17 |
| HypertensionVascular disorders | 2/17 | 4/17 |
| FlatulenceGastrointestinal disorders | 3/17 | 1/17 |
| NauseaGastrointestinal disorders | 2/17 | 3/17 |
| Blood creatinine increasedInvestigations | 3/17 | 3/17 |
| HyperkalaemiaMetabolism and nutrition disorders | 3/17 | 0/17 |
| HypomagnesaemiaMetabolism and nutrition disorders | 3/17 | 1/17 |
The two patients that were randomized but not does (one in eacj treatment arm) are not included in the demographics
| Age, Categorical(Participants) | LCP-Tacro | Prograf | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 16 | 32 |
| >=65 years | 1 | 1 | 2 |
| Age, Continuous(years) | LCP-Tacro | Prograf | Total |
|---|---|---|---|
| Mean | 51.5 ± 13.92 | 46.4 ± 11.49 | 49.0 ± 12.84 |
| Sex: Female, Male(Participants) | LCP-Tacro | Prograf | Total |
|---|---|---|---|
| Female | 3 | 8 | 11 |
| Male | 14 | 9 | 23 |
| Ethnicity (NIH/OMB)(Participants) | LCP-Tacro | Prograf | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 5 |
| Not Hispanic or Latino | 16 | 13 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LCP-Tacro | Prograf | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 10 |
| White | 10 | 12 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | LCP-Tacro | Prograf | Total |
|---|---|---|---|
| United States | 17 | 17 | 34 |
The record gives a start of Nov 2012, a primary completion of Mar 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus
Veloxis Pharmaceuticals